Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
202 hedge funds and large institutions have $3.05B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 69 increasing their positions, 65 reducing their positions, and 32 closing their positions.
53% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 32
43% more capital invested
Capital invested by funds: $2.13B → $3.05B (+$920M)
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
9% more funds holding
Funds holding: 186 → 202 (+16)
6% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 65
60% less call options, than puts
Call options by funds: $17.8M | Put options by funds: $44.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$160M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$46.8M |
| 3 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$29.6M |
| 4 |
DFO
Duquesne Family Office
New York
|
+$27.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
CPMG Inc
Dallas,
Texas
|
-$21.9M |
| 2 |
Millennium Management
New York
|
-$16.9M |
| 3 |
DM
Deerfield Management
New York
|
-$16.8M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$15.2M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$13.5M |
RETA Hedge Fund Activity: Q4 2020 in Review
202 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2020, worth a combined $3.05B — up 43% from $2.13B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new RETA positions and 32 closed out — a net gain of 17 holders — while 69 added to existing stakes and 65 trimmed.
The largest buyer was Invesco, adding an estimated $160M. The largest seller was CPMG Inc, cutting an estimated $21.9M.
- 202 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2020, up from 186 in Q3 2020.
- Funds reported $3.05B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2020, up 43% quarter-over-quarter.
- 49 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2020 and 32 closed out, a net change of +17 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q4 2020 was Invesco, an estimated $160M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2020 was CPMG Inc, an estimated $21.9M sold.
Based on aggregated 13F filings for Q4 2020.